Fibrinolytic parameters in children with noncatheter thrombosis: A pilot study

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 4, 2010, Pages 313-319

  Kupesiz, O Alphan ^a   Chitlur, Meera B ^b,c   Hollon, Wendy ^c   Tosun, Ozgun ^a   Thomas, Ronald ^b   Warrier, Indira ^b,c   Lusher, Jeanne M ^b,c   Rajpurkar, Madhvi ^b,c  

^a AKDENIZ UNIVERSITY   (Turkey)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Fibrinolysis; Noncatheter related thrombosis; Pediatric thrombosis; Thromboelastography

Indexed keywords

ENOXAPARIN; HEPARIN LYASE; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; GENDER; HUMAN; LUNG EMBOLISM; MALE; NONCATHETER RELATED DEEP VEIN THROMBOSIS; PATHOGENESIS; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBOSIS;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; FEMALE; FIBRIN; FIBRINOLYSIS; HUMANS; MALE; SEX FACTORS; THROMBELASTOGRAPHY; TISSUE PLASMINOGEN ACTIVATOR; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 77951907393     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833464ce     Document Type: Article

References (38)

1. Revel-Vilk S, Massicotte P. Thromboembolic diseases of childhood. Blood Rev 2003; 17: 1-6.
2. Schneppenheim R, Greiner J. Thrombosis in infants and children. Hematology Am Soc Hematol Educ Program 2006: 86-96.
3. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 5:e97.
4. Kwaan HC, Nabhan C. Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin North Am 2003; 17: 103-114.
5. Wichers IM, Tanck MW, Meijers JC, Lisman T, Reitsma PH, Rosendaal FR, et al. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost 2009; 101: 465-470.
6. Guimaraes AH, de Bruijne EL, Lisman T, Dippel DW, Deckers JW, Poldermans D, et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145: 115-120.
7. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009; 145: 121-127.
8. O. A Kupesiz MC, MA Rajpurkar, J Lusher, W Hollon, I Warrier. Tissue plasminogen activator (RTPA) induced fibrinolysis: standardization of method on thromboelastography. J Thromb Haemost 2007; 5: P-S-390.
9. Chitlur M, Warrier I, Rajpurkar M, Hollon W, Llanto L, Wiseman C, Lusher JM. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol 2008; 142: 250-256.
10. Manco-Johnson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, et al. Laboratory testing for thrombophiliainpediatric patients. On behalf of the Subcommittee for Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of ThrombosisandHaemostasis (ISTH). Thromb Haemost 2002; 88: 155-156. (Pubitemid 34752281)
11. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-1105.
12. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007; 12: 2957-2966.
13. Durina J, Remkova A. Prothrombotic state in metabolic syndrome. Bratisl Lek Listy 2007; 108: 279-280.
14. Palomo I, Alarcon M, Moore-Carrasco R, Argilés JM. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med 2006; 18: 969-974.
15. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008; 122: 736-742.
16. Komitopoulou A, Platokouki H, Kapsimali Z, Moschovi M, Kattamis A, Pergantou H, Aronis S. Mutations and polymorphisms in genes affecting haemostasis components in children with thromboembolic events. Pathophysiol Haemost Thromb 2006; 35: 392-397.
17. Komitopoulou A, Platokouki H, Kapsimali Z, Pergantou H, Adamtziki E, Aronis S. Mutations and polymorphisms in genes affecting hemostasis proteins and homocysteine metabolism in children with arterial ischemic stroke. Cerebrovasc Dis 2006; 22: 13-20.
18. Ozyurek E, Balta G, Degerliyurt A, Parlak H, Aysun S, Gürgey A. Significance of factor V, prothrombin, MTHFR, and PAI-1 genotypes in childhood cerebral thrombosis. Clin Appl Thromb Hemost 2007; 13: 154-160.
19. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) : how does thrombin regulate fibrinolysis? Ann Med 2006; 38: 378-388.
20. de Bruijne EL, Murad SD, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, et al. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost 2007; 97: 181-185.
21. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3: 2211-2218.
22. Leurs J, Hendriks D. Carboxypeptidase U (TAFIa) : a met al.locarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-487.
23. Lichy C, Dong-Si T, Reuner K, Genius J, Rickmann H, Hampe T, et al. Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems. J Neurol 2006; 253: 316-320.
24. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006; 134: 92-94.
25. Mutch NJ, Thomas L, Moore NR, Lisiak KM, Booth NA. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007; 5: 812-817.
26. Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, et al. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol 2008; 141: 716-719.
27. Willemse JL, Hendriks DF. A role for procarboxypepidase U (TAFI) in thrombosis. Front Biosci 2007; 12: 1973-1987.
28. Heller C, Heinecke A, Junker R, Knöfler R, Kosch A, Kurnik K, et al. Cerebral venous thrombosis in children: a multifactorial origin. Circulation 2003; 108: 1362-1367.
29. Nowak-Gottl U, Kosch A, Schlegel N, Salem M, Manco-Johnson M. Thromboembolism in children. Curr Opin Hematol 2002; 9: 448-453.
30. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003; 1: 915-921.
31. Senbil N, Yuksel D, Yilmaz D, Gü rer YK. Prothrombotic risk factors in children with hemiplegic cerebral palsy. Pediatr Int 2007; 49: 600-602.
32. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007; 120: 728-733.
33. Curnow JL, Morel-Kopp MC, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost 2007; 5: 528-534.
34. Goldenberg NA, Hathaway WE, Jacobson L, McFarland K, Manco-Johnson MJ. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A. Haemophilia 2006; 12: 605-614.
35. Rijken DC, Hoegee-de Nobel E, Jie AF, Atsma DE, Schalij MJ, Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 2008; 6: 151-157.
36. Stief TW, Frohlich S, Renz H. Determination of the global fibrinolytic state. Blood Coagul Fibrinolysis 2007; 18: 479-487.
37. Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ. Anew euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003; 112 (5-6) : 329-337.
38. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol 2007; 14: 242-248.